RxDoctor Payments Data

Richard Oneill, MD

Geriatric Medicine · Saint Louis, MONPI 1265570485

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 24.5% of the total. Reporting peaked in 2020 at $379 and has fallen 72.1% since, to $106 in 2023.

$1,411in general payments, 2019–2025

Across 80 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$346
  • Lilly USA, LLC$239
  • Amarin Pharma, Inc.$206
  • AbbVie$118
  • Johnson & Johnson$69
  • Pfizer$65
  • plus $367 from 15 others

What the payments were for

  • Food & beverage$1,411100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,411 in reported general payments places this provider in the 75th percentile of 76 geriatric medicine providers in Missouri.

See all geriatric medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$132,944
Medicare patients
377
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$72,378
OzempicSemaglutide40$56,515
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$34,559
JardianceEmpagliflozin30$32,786
JanuviaSitagliptin Phosphate16$24,102
XareltoRivaroxaban19$16,832
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen303$8,817
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$8,445
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen136$5,937
Memantine Hcl ErMemantine Hcl25$4,939
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$4,666
Levothyroxine Sodium387$4,572
Atorvastatin Calcium397$4,288
Albuterol Sulfate HfaAlbuterol Sulfate122$3,560
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$72,37865 claims
Novo NordiskOzempic$346$56,51540 claims
GSKTrelegy Ellipta, Anoro Ellipta$31$43,00464 claims
Boehringer IngelheimJardiance$14$32,78630 claims
MerckJanuvia$23$24,10216 claims
Johnson & JohnsonXarelto$69$16,83219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 76 geriatric medicine providers in Missouri.

Other geriatric medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →